• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在发现新型 cruzain 抑制剂中对接和高通量筛选的互补性。

Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors.

机构信息

Graduate Program in Chemistry and Chemical Biology, University of California San Francisco, California 94158, USA.

出版信息

J Med Chem. 2010 Jul 8;53(13):4891-905. doi: 10.1021/jm100488w.

DOI:10.1021/jm100488w
PMID:20540517
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2895358/
Abstract

Virtual and high-throughput screens (HTS) should have complementary strengths and weaknesses, but studies that prospectively and comprehensively compare them are rare. We undertook a parallel docking and HTS screen of 197861 compounds against cruzain, a thiol protease target for Chagas disease, looking for reversible, competitive inhibitors. On workup, 99% of the hits were eliminated as false positives, yielding 146 well-behaved, competitive ligands. These fell into five chemotypes: two were prioritized by scoring among the top 0.1% of the docking-ranked library, two were prioritized by behavior in the HTS and by clustering, and one chemotype was prioritized by both approaches. Determination of an inhibitor/cruzain crystal structure and comparison of the high-scoring docking hits to experiment illuminated the origins of docking false-negatives and false-positives. Prioritizing molecules that are both predicted by docking and are HTS-active yields well-behaved molecules, relatively unobscured by the false-positives to which both techniques are individually prone.

摘要

虚拟和高通量筛选 (HTS) 应该具有互补的优势和劣势,但很少有前瞻性和全面比较它们的研究。我们对 197861 种化合物进行了平行对接和 HTS 筛选,以寻找针对恰加斯病的硫醇蛋白酶靶点 cruzain 的可逆竞争性抑制剂。在研究过程中,99%的命中化合物被作为假阳性而淘汰,只得到了 146 种表现良好的竞争性配体。这些配体分为五种化学型:两种化学型根据对接排名库中得分在前 0.1%的情况进行了优先级排序,两种化学型根据 HTS 中的行为和聚类进行了优先级排序,还有一种化学型根据这两种方法都进行了优先级排序。确定抑制剂/cruzain 晶体结构并将高得分对接命中化合物与实验进行比较,阐明了对接假阴性和假阳性的起源。优先考虑既可以通过对接预测又可以在 HTS 中发挥活性的分子,可以得到表现良好的分子,相对不受两种技术各自容易出现的假阳性的干扰。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/58141fb7a483/jm-2010-00488w_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/a895c3e44cdc/jm-2010-00488w_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/4a2bc65f5927/jm-2010-00488w_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/0a8ab64d8bef/jm-2010-00488w_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/827d2ef60169/jm-2010-00488w_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/68c951d3f56b/jm-2010-00488w_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/c9e73bf0aaa8/jm-2010-00488w_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/e17c633af936/jm-2010-00488w_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/58141fb7a483/jm-2010-00488w_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/a895c3e44cdc/jm-2010-00488w_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/4a2bc65f5927/jm-2010-00488w_0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/0a8ab64d8bef/jm-2010-00488w_0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/827d2ef60169/jm-2010-00488w_0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/68c951d3f56b/jm-2010-00488w_0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/c9e73bf0aaa8/jm-2010-00488w_0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/e17c633af936/jm-2010-00488w_0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e09f/2895358/58141fb7a483/jm-2010-00488w_0001.jpg

相似文献

1
Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors.在发现新型 cruzain 抑制剂中对接和高通量筛选的互补性。
J Med Chem. 2010 Jul 8;53(13):4891-905. doi: 10.1021/jm100488w.
2
Cruzain inhibitors: efforts made, current leads and a structural outlook of new hits.克扎瑞安抑制剂:已有的努力、当前的先导物和新发现的结构展望。
Drug Discov Today. 2015 Jul;20(7):890-8. doi: 10.1016/j.drudis.2015.02.004. Epub 2015 Feb 16.
3
Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.开发基于α-酮的克氏锥虫蛋白酶抑制剂,该蛋白酶是一种与恰加斯病相关的半胱氨酸蛋白酶。
Bioorg Med Chem. 2005 Mar 15;13(6):2141-56. doi: 10.1016/j.bmc.2004.12.053.
4
Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.具有改善药代动力学性质的四氟苯氧基甲基酮克鲁兹蛋白酶抑制剂作为恰加斯病的治疗先导物。
Bioorg Med Chem Lett. 2015 Nov 1;25(21):4834-4837. doi: 10.1016/j.bmcl.2015.06.066. Epub 2015 Jun 23.
5
Molecular Design, Synthesis and Trypanocidal Activity of Dipeptidyl Nitriles as Cruzain Inhibitors.作为克鲁兹蛋白酶抑制剂的二肽基腈的分子设计、合成及杀锥虫活性
PLoS Negl Trop Dis. 2015 Jul 14;9(7):e0003916. doi: 10.1371/journal.pntd.0003916. eCollection 2015.
6
A structure-based virtual high-throughput screening, molecular docking, molecular dynamics and MM/PBSA study identified novel putative drug-like dual inhibitors of trypanosomal cruzain and rhodesain cysteine proteases.基于结构的虚拟高通量筛选、分子对接、分子动力学和 MM/PBSA 研究鉴定了新型潜在的双抑制剂,用于抑制锥虫 cruzain 和 rhodesain 半胱氨酸蛋白酶。
Mol Divers. 2024 Apr;28(2):531-551. doi: 10.1007/s11030-023-10600-2. Epub 2023 Jan 8.
7
Cruzain : the path from target validation to the clinic.克扎林:从靶标验证到临床应用的途径。
Adv Exp Med Biol. 2011;712:100-15. doi: 10.1007/978-1-4419-8414-2_7.
8
Chemoinformatics Studies on a Series of Imidazoles as Cruzain Inhibitors.作为克氏锥虫抑制剂的一系列咪唑类化合物的 chemoinformatics 研究。
Biomolecules. 2021 Apr 15;11(4):579. doi: 10.3390/biom11040579.
9
Aryl ureas represent a new class of anti-trypanosomal agents.芳基脲类是一类新型抗锥虫剂。
Chem Biol. 2000 Sep;7(9):733-42. doi: 10.1016/s1074-5521(00)00018-1.
10
Novel cruzain inhibitors for the treatment of Chagas' disease.新型克氏锥虫抑制剂用于治疗恰加斯病。
Chem Biol Drug Des. 2012 Sep;80(3):398-405. doi: 10.1111/j.1747-0285.2012.01416.x. Epub 2012 Jun 27.

引用本文的文献

1
Potent Inhibition of Chikungunya Virus Entry by a Pyrazole-Benzene Derivative: A Computational Study Targeting the E1-E2 Glycoprotein Complex.吡唑 - 苯衍生物对基孔肯雅病毒进入的强效抑制作用:针对E1 - E2糖蛋白复合物的计算研究
Int J Mol Sci. 2025 Jul 5;26(13):6480. doi: 10.3390/ijms26136480.
2
Investigation of the activity of 4-aminoquinolines as cysteine protease inhibitors with application in the treatment of Chagas disease.4-氨基喹啉作为半胱氨酸蛋白酶抑制剂的活性研究及其在恰加斯病治疗中的应用。
Mem Inst Oswaldo Cruz. 2025 Feb 7;120:e240161. doi: 10.1590/0074-02760240161. eCollection 2025.
3
Synthesis and Biological Evaluation of New Chalcogen Semicarbazone (, ) and Their Azole Derivatives against Chagas Disease.

本文引用的文献

1
Integration of virtual and physical screening.虚拟筛选与实体筛选的整合
Drug Discov Today Technol. 2006 Winter;3(4):377-385. doi: 10.1016/j.ddtec.2006.11.003. Epub 2006 Dec 14.
2
Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.鉴定和优化克氏锥虫半胱氨酸蛋白酶抑制剂:克氏锥虫 cruzain、rhodesain 和 TbCatB。
J Med Chem. 2010 Jan 14;53(1):52-60. doi: 10.1021/jm901069a.
3
Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease.
合成与新的含硫半卡巴腙( , )及其唑类衍生物的生物评价对恰加斯病。
J Med Chem. 2024 Nov 14;67(21):19038-19056. doi: 10.1021/acs.jmedchem.4c01535. Epub 2024 Nov 1.
4
ChemFH: an integrated tool for screening frequent false positives in chemical biology and drug discovery.ChemFH:一种用于筛选化学生物学和药物发现中常见假阳性的综合工具。
Nucleic Acids Res. 2024 Jul 5;52(W1):W439-W449. doi: 10.1093/nar/gkae424.
5
Integrated Computational Approaches for Drug Design Targeting Cruzipain.靶向 cruzipain 的药物设计的综合计算方法。
Int J Mol Sci. 2024 Mar 27;25(7):3747. doi: 10.3390/ijms25073747.
6
Drug Discovery Efforts to Identify Novel Treatments for Neglected Tropical Diseases - Cysteine Protease Inhibitors.药物研发努力:寻找新型治疗方法以应对被忽视的热带病——半胱氨酸蛋白酶抑制剂。
Curr Med Chem. 2024;31(16):2170-2194. doi: 10.2174/0109298673249097231017051733.
7
Convergent QSAR Models for the Prediction of Cruzain Inhibitors.用于预测克鲁兹蛋白酶抑制剂的收敛性定量构效关系模型
ACS Omega. 2023 Oct 13;8(42):38961-38982. doi: 10.1021/acsomega.3c03376. eCollection 2023 Oct 24.
8
Next-generation intelligent laboratories for materials design and manufacturing.用于材料设计与制造的下一代智能实验室。
MRS Bull. 2023;48(2):179-185. doi: 10.1557/s43577-023-00481-z. Epub 2023 Feb 27.
9
Screening the Pathogen Box to Discover and Characterize New Cruzain and CatL Inhibitors.筛选病原体文库以发现和鉴定新型克氏锥虫蛋白酶和组织蛋白酶L抑制剂。
Pathogens. 2023 Feb 4;12(2):251. doi: 10.3390/pathogens12020251.
10
A structure-based virtual high-throughput screening, molecular docking, molecular dynamics and MM/PBSA study identified novel putative drug-like dual inhibitors of trypanosomal cruzain and rhodesain cysteine proteases.基于结构的虚拟高通量筛选、分子对接、分子动力学和 MM/PBSA 研究鉴定了新型潜在的双抑制剂,用于抑制锥虫 cruzain 和 rhodesain 半胱氨酸蛋白酶。
Mol Divers. 2024 Apr;28(2):531-551. doi: 10.1007/s11030-023-10600-2. Epub 2023 Jan 8.
定量分析在筛选巯基蛋白酶抑制剂的过程中出现的聚集、自发荧光和反应性伪影。
J Med Chem. 2010 Jan 14;53(1):37-51. doi: 10.1021/jm901070c.
4
Predicting new molecular targets for known drugs.预测已知药物的新分子靶标。
Nature. 2009 Nov 12;462(7270):175-81. doi: 10.1038/nature08506. Epub 2009 Nov 1.
5
Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases.新型非肽类乙烯砜类化合物靶向寄生虫半胱氨酸蛋白酶的 S2 和 S3 亚基。
Bioorg Med Chem Lett. 2009 Nov 1;19(21):6218-21. doi: 10.1016/j.bmcl.2009.08.098. Epub 2009 Sep 3.
6
Prediction of the water content in protein binding sites.蛋白质结合位点中含水量的预测。
J Phys Chem B. 2009 Oct 8;113(40):13337-46. doi: 10.1021/jp9047456.
7
Importance of ligand reorganization free energy in protein-ligand binding-affinity prediction.配体重组自由能在蛋白质-配体结合亲和力预测中的重要性。
J Am Chem Soc. 2009 Sep 30;131(38):13709-21. doi: 10.1021/ja9039373.
8
Divergent modes of enzyme inhibition in a homologous structure-activity series.在同源结构-活性系列中,酶抑制的不同模式。
J Med Chem. 2009 Aug 27;52(16):5005-8. doi: 10.1021/jm9009229.
9
Structure-based discovery of beta2-adrenergic receptor ligands.基于结构的β2-肾上腺素能受体配体的发现
Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6843-8. doi: 10.1073/pnas.0812657106. Epub 2009 Apr 2.
10
Exploiting ordered waters in molecular docking.在分子对接中利用有序水
J Med Chem. 2008 Aug 28;51(16):4862-5. doi: 10.1021/jm8006239. Epub 2008 Aug 5.